Group 1 - The core viewpoint is that Precision Science expects to achieve profitability by 2026, with revenue forecasts of $3.227 billion, $3.613 billion, and $4.053 billion for 2025 to 2027, respectively, and a net profit improvement from a loss of $58 million in 2025 to a profit of $82 million in 2026 [1] - The company raised its full-year revenue guidance for 2025 to between $3.22 billion and $3.235 billion during the Q3 earnings call on November 3, 2025, with an adjusted EBITDA target of $470 million to $480 million [1] Group 2 - Abbott announced plans to acquire Exact Sciences, which could accelerate the company's international expansion [2] - The launch of the multi-cancer early detection test, Cancer Guard, in Q3 2025 will be a key factor for business growth based on its commercialization progress and market acceptance [2] Group 3 - The Cologuard product is driving an increase in screening numbers, with a year-on-year increase of 250,000 people in Q3 2025, supported by brand strength and execution efficiency [3] - The company is enhancing profit margins through laboratory optimization and supply chain management, with a focus on cost control and operational efficiency planned for 2026 [3]
精密科学预计2026年扭亏为盈，业务与战略合作持续推进
Jing Ji Guan Cha Wang·2026-02-12 20:03